Format

Send to

Choose Destination
See comment in PubMed Commons below
Med Monatsschr Pharm. 2009 Nov;32(11):402-7.

[Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].

[Article in German]

Author information

1
ellen.jahn@t-online.de

Abstract

The GLP-1-receptor-agonist liraglutide (Victoza) has been approved for the treatment of diabetes mellitus type 2 in Europe. Liraglutide is the first human GLP-1 analogue which is applied once a day. Efficacy and safety of liraglutide were investigated in the broad LEAD-study-programme in comparison with placebo and other common therapeutics for the treatment of diabetes mellitus type 2. Liraglutide has been approved for the combination with metformin and/or a sulfonylurea or with metformin and a thiazolidinedione, if treatment with one or a combination of these drugs is not sufficient for an adequate blood glucose control.

PMID:
19947303
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center